CL2021000627A1 - Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular - Google Patents

Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Info

Publication number
CL2021000627A1
CL2021000627A1 CL2021000627A CL2021000627A CL2021000627A1 CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1 CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1
Authority
CL
Chile
Prior art keywords
joint
treatment
pharmaceutical compositions
compositions suitable
joint pain
Prior art date
Application number
CL2021000627A
Other languages
English (en)
Spanish (es)
Inventor
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Lo Chang
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of CL2021000627A1 publication Critical patent/CL2021000627A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021000627A 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular CL2021000627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16

Publications (1)

Publication Number Publication Date
CL2021000627A1 true CL2021000627A1 (es) 2021-09-10

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000627A CL2021000627A1 (es) 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Country Status (15)

Country Link
US (1) US12208104B2 (enExample)
EP (1) EP3849522A1 (enExample)
JP (1) JP7634476B2 (enExample)
KR (1) KR20210060559A (enExample)
CN (1) CN112702993A (enExample)
AU (1) AU2019339528B2 (enExample)
BR (1) BR112021004880A2 (enExample)
CA (1) CA3112234A1 (enExample)
CL (1) CL2021000627A1 (enExample)
IL (1) IL281513A (enExample)
MX (1) MX2021003030A (enExample)
SG (1) SG11202102400PA (enExample)
TW (1) TWI843751B (enExample)
WO (1) WO2020056399A1 (enExample)
ZA (1) ZA202101688B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230048066A (ko) * 2020-08-05 2023-04-10 티엘씨 바이오파머슈티컬즈 인코포레이티드 통증 조절용 관절내 코르티코스테로이드의 약학 조성물
WO2024230405A1 (zh) * 2023-05-05 2024-11-14 中南大学湘雅医院 氢氧化镁在制备治疗关节疼痛的药物中的应用
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
RU2660585C2 (ru) 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
SI2854769T1 (sl) 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa

Also Published As

Publication number Publication date
JP2022500364A (ja) 2022-01-04
MX2021003030A (es) 2021-05-27
US12208104B2 (en) 2025-01-28
AU2019339528B2 (en) 2025-01-30
BR112021004880A2 (pt) 2021-06-01
TW202023569A (zh) 2020-07-01
ZA202101688B (en) 2024-06-26
TWI843751B (zh) 2024-06-01
SG11202102400PA (en) 2021-04-29
CA3112234A1 (en) 2020-03-19
AU2019339528A1 (en) 2021-04-15
IL281513A (en) 2021-04-29
US20210338688A1 (en) 2021-11-04
JP7634476B2 (ja) 2025-02-21
CN112702993A (zh) 2021-04-23
WO2020056399A1 (en) 2020-03-19
EP3849522A1 (en) 2021-07-21
KR20210060559A (ko) 2021-05-26

Similar Documents

Publication Publication Date Title
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PE20242299A1 (es) Composiciones agonistas de gip/glp1
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
AR098989A1 (es) Composiciones farmacéuticas que comprenden azd9291
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
DOP2019000071A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR100153A1 (es) Medicamento
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
AR134203A1 (es) Compuestos para la degradación de braf mutante
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos